Innerworld@lemmy.worldM to Mergers and Acquisitions (M&A)@lemmy.worldEnglish · 4 days agoHong Kong-listed drug design tech firm Metis TechBio granted U.S.-based biotechnology firm Boulevard Bio exclusive global rights to its experimental autoimmune drug MTS-128 in deal worth up to $1.6Bwww.reuters.comexternal-linkmessage-square0linkfedilinkarrow-up11arrow-down10
arrow-up11arrow-down1external-linkHong Kong-listed drug design tech firm Metis TechBio granted U.S.-based biotechnology firm Boulevard Bio exclusive global rights to its experimental autoimmune drug MTS-128 in deal worth up to $1.6Bwww.reuters.comInnerworld@lemmy.worldM to Mergers and Acquisitions (M&A)@lemmy.worldEnglish · 4 days agomessage-square0linkfedilink
